Prot #C34002: An Open-Label, Phase 1b/2 Study Investigating Recommended Phase 2 Dose, Safety, Tolerability, and Preliminary Efficacy of TAK-659 in Adult Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)

Project: Research project

Project Details

StatusActive
Effective start/end date2/25/152/28/21

Funding

  • Quintiles, Inc. (Prot #C34002)
  • Millennium Pharmaceuticals, Inc (Prot #C34002)